• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

FDA chief: Changing generics regulations could reel in drug prices

May 25, 2017 By Sarah Faulkner

FDAPart of the FDA commissioner’s job is to oversee the federal regulatory watchdog as it evaluates pharmaceuticals for safety and efficacy. Most FDA chiefs have avoided the topic of drug prices, given that it isn’t a clearly-stated part of the agency’s mission

But just 2 weeks into the job, newly-confirmed FDA commish Dr. Scott Gottlieb proposed a plan, called the Drug Competition Action Plan, that he believes will help restrain the cost of prescription drugs.

As he testified before the House appropriations subcommittee that’s deciding the FDA’s 2018 fiscal budget, Gottlieb said that helping generics gain access to the market could bring down the prices for expensive brand name pharmaceuticals.

“Simply put, too many patients are priced out of the medicines they need,” Gottlieb said, according to The Wall Street Journal. “While the FDA does not have a direct role in drug pricing, we can take steps to facilitate entry of lower-cost alternatives to the market, and increase competition.”

The commissioner called on the FDA to accelerate the application review process to eliminate the backlog of 2,640 applications. Nearly 1,500 of those applications have been sent back to sponsors with requests for changes.

Gottlieb also suggested that the FDA could regularly publish lists of older medicines that don’t have generic competition, to encourage generics-makers into the market.

Under current FDA standards, it’s challenging to prove equivalence to “complex” drugs, like medications administered using an inhaler. Because of this, there are a number of products that are off patent but still don’t have generic competition – including Mylan‘s (NSDQ:MYL) EpiPen. Gottlieb said the FDA could make the review process simpler in order to get generics to the market.

He also said the agency should intervene in cases in which a brand-name drugmaker is accused of using FDA rules to refuse to make a drug available to generic manufacturers.

“The FDA has an important role to play in making sure that its statutory and regulatory processes are working as intended, and not being manipulated in ways that FDA and Congress did not intend,” he said.

Filed Under: Featured, Food & Drug Administration (FDA), Pharmaceuticals, Policy Tagged With: Mylan

IN CASE YOU MISSED IT

  • 8 drug delivery innovations you need to know
  • Axonics acquires Contura and its Bulkamid bulking agent for $235M
  • Lilly to add Welldoc app to future insulin pen
  • Kala Pharmaceuticals slides on missed Q4 projections
  • Semaglutide paired with behavioral therapy tripled weight loss in trial

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Footer

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Design & Outsourcing
Medical Tubing + Extrusion

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery News
Advertise with us
About
Contact us
Privacy
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2021 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS